Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality
Abstract Chimeric antigen receptors (CARs) are engineered to target T cells specifically to tumor cells, resulting in the engineered T cell killing the tumor cell. This technology has been developed to target a range of cancers, with the most notable successes in the treatment of B-cell malignancies...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2023-07-01
|
| Col·lecció: | Journal of Translational Medicine |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12967-023-04372-4 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|